Large-scale testing (Phase 3)Study completedNCT05372419
What this trial is testing
(LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Who this might be right for
Atopic Dermatitis
Eli Lilly and Company 90